These observations provide a mechanistic rationale for its pro-tumor behavior in glioblastoma, while reinforcing that in other cancers, precise modulation of GSDME via epigenetic activation or inhibition remains a promising therapeutic strategy. The gene discussed is GSDME; the disease is glioblastoma.